about
An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?Drug-drug plasma protein binding interactions of ivacaftor.Antibiotic-non-antibiotic combinations for combating extremely drug-resistant Gram-negative 'superbugs'.A traceless reversible polymeric colistin prodrug to combat multidrug-resistant (MDR) gram-negative bacteria.Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO.Rapamycin confers neuroprotection against colistin-induced oxidative stress, mitochondria dysfunction and apoptosis through the activation of autophagy and mTOR/Akt/CREB signaling pathways.A Portrait of the Sialyl Glycan Receptor Specificity of the H10 Influenza Virus Hemagglutinin-A Picture of an Avian Virus on the Verge of Becoming a Pandemic?Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.Hydrolyzable Poly[Poly(Ethylene Glycol) Methyl Ether Acrylate]-Colistin Prodrugs through Copper-Mediated Photoinduced Living Radical Polymerization.Broad activity of diphenyleneiodonium analogues against Mycobacterium tuberculosis, malaria parasites and bacterial pathogens.Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes.Gelofusine Ameliorates Colistin-Induced Nephrotoxicity.Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules.The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites.A Comparative Study of Outer Membrane Proteome between Paired Colistin-Susceptible and Extremely Colistin-Resistant Klebsiella pneumoniae StrainsMechanistic Insights From Global Metabolomics Studies into Synergistic Bactericidal Effect of a Polymyxin B Combination With Tamoxifen Against Cystic Fibrosis MDRMolecular Mechanisms of Neurotoxicity Induced by Polymyxins and ChemopreventionContemporary Anti-Ebola Drug Discovery Approaches and PlatformsBeyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosisThe impact of backbone N-methylation on the structure-activity relationship of Leu10 -teixobactin
P50
Q37634327-68CD02E1-0166-4881-AA57-4D160382965EQ38996435-7DB219B8-6F42-483A-892D-0C251F52C457Q39036218-C47A4A38-382C-475F-BCEC-C9EF00EEB424Q39160503-33BA6DBD-8677-4403-8D01-40824C79413AQ40341249-883EA8DE-1CF7-4D2A-AC48-CBBDA2488335Q45055159-C0014F8D-D212-47BA-8E03-A4F70EBE9A6EQ46236586-D76A0300-FF04-4CBD-8A68-6D7AD5745B5FQ46242247-1C9EA635-187F-4AAE-B3E3-17DF6DF19107Q47691167-F337FBEB-B7C6-4CF3-AF9C-1D203BA718C0Q47990386-34285F51-EA2D-42CD-AB16-8F23D3BBD187Q48020066-4420BE24-BBC2-4008-A907-3BFD37BCD7A3Q48146758-3BB6AA14-8B95-4EEB-B155-82C9338645FEQ50035129-7E6C6622-231D-4B31-AD7A-3C35E1BE5D3EQ51736541-9F765737-97F7-4B97-B5B9-D56955F0B356Q52645796-E4579DE9-9F3E-40C6-AD49-63F0104B88B7Q59201259-E263AE0C-139C-47D3-9411-EAEC062E0286Q59792334-7E27DA8F-F048-4917-B123-F0D4EADA7986Q64027814-1EAFD4DD-346B-4D21-B823-8549FCD6BD71Q64027815-7E9D4585-3720-4F78-85DA-63B7B0055E15Q91841929-E9D3A226-AC1A-46E5-99A7-E6A6F2A5068CQ92467090-BF577B22-E7D6-49B4-BE8B-8D0E39522C74
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elena K. Schneider-Futschik
@ast
Elena K. Schneider-Futschik
@en
Elena K. Schneider-Futschik
@es
Elena K. Schneider-Futschik
@nl
type
label
Elena K. Schneider-Futschik
@ast
Elena K. Schneider-Futschik
@en
Elena K. Schneider-Futschik
@es
Elena K. Schneider-Futschik
@nl
prefLabel
Elena K. Schneider-Futschik
@ast
Elena K. Schneider-Futschik
@en
Elena K. Schneider-Futschik
@es
Elena K. Schneider-Futschik
@nl
P106
P31
P496
0000-0001-6044-4824